^
Association details:
| Biomarker: | FGFR3 Y375C |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Truseltiq (infigratinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Excerpt:
A decrease in FGFR3 mutations with BGJ398 treatment appeared to correlate with a longer time on study and a greater percentage decrease in tumor size from baseline...An analysis of clinical outcome limited to patients with documented activating mutations in FGFR3 (S249C, R248C, Y375C and Y373C) yields a confirmed response rate of 28.6% (16 of 56 patients); including unconfirmed responses, the response rate rises further to 42.9% (24 of 56 patients).
DOI:
10.1158/2159-8290.CD-18-0229
